Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma

Shahin Yazdani, Kamran Hendi, Mohammad Pakravan

Research output: Contribution to journalArticlepeer-review


Purpose: To report two cases with neovascular glaucoma secondary to ischemic central retinal vein occlusion (CRVO) who were treated with intravitreal bevacizumab. Case Report: Two patients were referred for neovascular glaucoma following CRVO. Visual acuity was light perception. Both eyes had extensive iris neovascularization (NVI), synechial angle closure and high intraocular pressure (IOP) in spite of antiglaucoma medications. After obtaining informed consent, both eye received an intravitreal injection of 2.5 mg (0.1 ml) bevacizumab (Avastin). Both eyes demonstrated dramatic IOP reduction together with decreased severity and extent of NVI during 4 weeks of follow up. Visual acuity remained unchanged. Conclusion: Despite the dramatic short-term response in terms of IOP reduction and regression of neovascularization, due to limited clinical experience, one should consider this novel indication for bevacizumab cautiously.

Original languageEnglish (US)
Pages (from-to)129-132
Number of pages4
JournalJournal of Ophthalmic and Vision Research
Issue number2
StatePublished - 2006
Externally publishedYes

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma'. Together they form a unique fingerprint.

Cite this